Your Cart is Empty
NEW THCA FLOWER IN STOCK - FREE SHIPPING ON ALL U.S. ORDERS $100+
NEW THCA FLOWER IN STOCK - FREE SHIPPING ON ALL U.S. ORDERS $100+
NEW THCA FLOWER IN STOCK - FREE SHIPPING ON ALL U.S. ORDERS $100+
August 15, 2021 11 min read
Cannabigerol (CBG) is a naturally occurring cannabinoid found in the Cannabis sativa plant, which includes hemp and marijuana varieties. Often called the “mother of all cannabinoids,” CBG is gaining attention for its potential wellness applications, including stress management, mood support, and physical recovery.
Unlike tetrahydrocannabinol (THC), the cannabinoid primarily responsible for the intoxicating effects of marijuana, CBG is generally considered non-intoxicating. This makes cannabigerol an interesting subject for researchers exploring the potential benefits of cannabis-derived compounds without the traditional marijuana high.
Interest in CBG oil, hemp-derived CBG supplements, and other cannabigerol products continues to grow across the United States, including Virginia. However, an important question remains: What does scientific research actually say about CBG, and is it legal to buy and use?
In this guide, we explore what cannabigerol is, its potential benefits, possible side effects, the differences between CBG and CBD, and the current legal considerations for consumers in the USA and Virginia.
Cannabigerol, commonly abbreviated as CBG, is one of the many cannabinoids produced by the cannabis plant. Cannabinoids are chemical compounds that interact with biological systems in the human body.
CBG is particularly interesting because its acidic precursor, cannabigerolic acid (CBGA), contributes to the formation of several other cannabinoids during plant development. Depending on the plant's genetics and biochemical processes, CBGA can be converted into precursors of cannabinoids such as THC and CBD.
Once extracted and purified, CBG can be used as an ingredient in products such as oils, tinctures, capsules, and other cannabinoid formulations.
CBG is generally described as non-intoxicating, meaning it is not expected to produce the characteristic marijuana high associated with THC.
However, non-intoxicating does not automatically mean completely free of side effects, suitable for everyone, or guaranteed not to affect alertness. Research into the effects of CBG in humans is still developing.
Researchers are investigating how cannabigerol interacts with cannabinoid receptors and other biological signaling systems. These interactions may help explain why CBG has attracted scientific interest in areas such as stress, inflammation, and neurological health.
Much of the proposed mechanism of action comes from laboratory and preclinical research. More high-quality human studies are needed to establish whether these effects translate into meaningful health benefits.
People searching for CBG benefits often want to understand whether cannabigerol can support relaxation, mood, sleep, discomfort, or general wellness.
Early research is promising in some areas, but the evidence remains limited. CBG should not be presented as a proven treatment for a medical condition.
One of the most discussed potential benefits of CBG is its possible role in managing stress.
A small, placebo-controlled human study published in Scientific Reports in 2024 examined 20 mg of hemp-derived CBG in 34 healthy adults. Researchers observed reductions in self-reported anxiety and stress after CBG administration compared with placebo under the study conditions.
These findings are encouraging, but the study was small and examined short-term effects. Larger studies are necessary to determine whether CBG consistently helps with stress and whether any benefits persist with repeated use.
What this means: CBG may be worth studying as a potential wellness ingredient, but it is not an established treatment for anxiety disorders or chronic stress.
Source: Cuttler et al., Scientific Reports (2024).
Another area of interest is the potential relationship between cannabigerol and mood.
Preclinical research has explored how CBG may affect biological pathways involved in mood regulation. Preliminary human research has also examined subjective mood outcomes.
However, evidence that CBG can reliably improve mood or treat depression remains insufficient. Consumers should be cautious about products marketed with claims that CBG cures depression or replaces prescribed mental health treatment.
Inflammation is a normal biological response that helps the body respond to injury and other challenges. Persistent or excessive inflammation is associated with many health conditions.
Laboratory and animal studies suggest that CBG may influence certain pathways involved in inflammatory responses. These findings have led to interest in cannabigerol for inflammation-related research.
Nevertheless, results from laboratory studies do not establish that taking CBG oil or supplements reduces inflammation in humans. Clinical research is needed before specific anti-inflammatory benefits can be confirmed.
Some consumers are interested in CBG products for exercise recovery, muscle soreness, and post-workout comfort.
Researchers have begun examining cannabinoid formulations for these purposes, but evidence specifically establishing CBG as an effective recovery supplement is limited.
People considering CBG for exercise recovery should also account for established approaches such as adequate sleep, nutrition, hydration, and appropriate training recovery.
CBG is sometimes marketed for relaxation and sleep support. However, evidence that CBG independently improves sleep quality, reduces insomnia, or helps people fall asleep faster is not yet conclusive.
The effects may also differ depending on the formulation. Products containing CBG alongside CBD, THC, melatonin, or other ingredients cannot be assumed to have the same effects as CBG alone.
Anyone experiencing persistent sleep difficulties should discuss the underlying cause and appropriate treatment options with a qualified healthcare professional.
Scientists are exploring how CBG interacts with biological pathways relevant to the nervous system. Early preclinical findings have generated interest in its possible neurological applications.
However, these findings do not establish CBG as a treatment for neurodegenerative diseases, epilepsy, or other neurological conditions. Such claims require rigorous clinical evidence and appropriate regulatory approval.
A 2026 human laboratory study investigated oral CBG in 12 healthy adults using single doses ranging from 25 mg to 200 mg. Researchers reported that CBG was generally well tolerated during the study, but observed few robust effects. The authors emphasized the need for research examining repeated or long-term use.
This is an important distinction: early studies can help researchers understand how CBG behaves in the human body, but they do not establish its long-term safety or effectiveness as a treatment.
Source: The Journal of Pharmacology and Experimental Therapeutics (2026).
CBG and CBD are both cannabinoids found in cannabis plants, but they differ in their chemical structures, concentrations in many cannabis varieties, and the amount of research available for each compound.
| Feature | CBG (Cannabigerol) | CBD (Cannabidiol) |
|---|---|---|
| Source | Hemp and other cannabis varieties | Hemp and other cannabis varieties |
| Intoxicating effects | Generally considered non-intoxicating | Generally considered non-intoxicating |
| Research status | Limited human evidence | More extensively studied, though evidence varies by use |
| Common product formats | Oils, tinctures, capsules, blends | Oils, tinctures, capsules, topicals, blends |
| Potential wellness uses | Under investigation for stress, mood, and other effects | Studied for several potential applications |
| FDA-approved prescription use | No CBG medicine currently established as FDA-approved | Epidiolex, a prescription CBD medicine, is FDA-approved for specific seizure disorders |
| Legal considerations | Depends on source, formulation, THC content, product type, and applicable laws | Depends on source, formulation, THC content, product type, and applicable laws |
Neither cannabinoid is universally better than the other. The appropriate choice depends on a person's goals, the specific formulation, available evidence, and individual circumstances.
CBD has a larger body of research than CBG, although many consumer wellness claims about CBD also remain unproven. CBG has a smaller and newer evidence base.
Consumers should compare products based on verified ingredients, independent laboratory testing, and transparent labeling rather than relying on claims that one cannabinoid is inherently superior.
CBG's legal status in the United States depends on the source of the cannabinoid, the product's composition, how it is marketed, and applicable federal and state laws.
Hemp-derived CBG may be lawful under certain circumstances, but it is not accurate to assume that every CBG product is automatically legal.
The federal 2018 Farm Bill established a definition of hemp based on a delta-9 THC concentration of no more than 0.3% on a dry-weight basis. It also removed qualifying hemp from the federal Controlled Substances Act's definition of marijuana.
However, the distinction between hemp and marijuana does not exempt every cannabinoid product from other federal requirements.
The U.S. Food and Drug Administration (FDA) retains authority over applicable cannabis-derived products under federal food, drug, and cosmetic laws. Whether a CBG product can legally be marketed for a particular use depends on factors including its ingredients, intended use, labeling, and regulatory classification.
For example, a seller cannot assume that labeling a product as hemp-derived automatically makes it lawful to market as a dietary supplement or as a treatment for a disease.
Consumers should consult current federal guidance and applicable state laws before purchasing or selling CBG products.
Official source: U.S. Food and Drug Administration, FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD).
For consumers searching for CBG legality in Virginia, state-specific regulations are particularly important.
Virginia regulates hemp-derived products intended for human consumption, including certain edible and inhalable hemp products. The state's Cannabis Control Authority (CCA) provides guidance on regulated hemp products, retailer registration, and compliance requirements.
As of October 2026, Virginia has implemented significant changes to its hemp-product rules. Beginning August 15, 2026, regulated hemp products produced or sold in Virginia cannot contain more than 2 milligrams of total THC per package under the applicable state requirements.
Virginia also requires regulated hemp-product retail facilities to register as required by law. Additional requirements can apply to product labeling, packaging, testing, and manufacturing.
These rules are especially important when evaluating full-spectrum CBG products, which may contain THC alongside CBG and other cannabinoids.
The answer depends on the particular product and the applicable rules.
Before purchasing CBG oil, CBG gummies, or another hemp-derived cannabinoid product in Virginia, consumers should:
A product sold legally in another state is not necessarily compliant with Virginia's requirements.
For the most current information, consult the Virginia Cannabis Control Authority's official hemp information page and the applicable provisions of the Code of Virginia.
Official sources:
Although early research suggests that CBG can be tolerated by some adults in the short term, its safety profile is not yet fully understood.
Possible side effects reported or discussed in connection with cannabinoid products include:
The actual risks may vary according to the dose, formulation, other cannabinoids present, individual health factors, and medications being taken.
Potential interactions are an important consideration because cannabinoid products may affect how certain medications are processed or how their effects are experienced.
If you take prescription medication, have an ongoing health condition, or are considering CBG for a specific medical concern, speak with a healthcare professional before use.
People who are pregnant or breastfeeding should avoid using CBG products unless advised otherwise by an appropriate healthcare professional, because adequate safety data are lacking.
Do not drive or operate machinery if a product causes drowsiness or impairment. Also, remember that a product labeled non-intoxicating may contain other cannabinoids, including THC.
If you are considering a CBG oil, tincture, capsule, or other hemp-derived product, product quality and accurate labeling matter.
Choose products that provide a recent certificate of analysis (COA) from an independent laboratory.
Ideally, the report should identify the amounts of CBG, CBD, THC, and other relevant cannabinoids, along with testing for contaminants where appropriate.
Products may contain different cannabinoid profiles:
Product definitions and actual ingredient profiles can vary by manufacturer, so check the label and laboratory report.
Compare the amount of CBG per serving with the amount per package. Check for additional cannabinoids, flavorings, sweeteners, or other active ingredients.
Do not assume that a higher concentration provides greater benefits or that products with similar names have equivalent effects.
Be cautious of products advertised as cures for anxiety, chronic pain, cancer, insomnia, or other diseases.
The evidence for CBG is still developing, and marketing claims do not substitute for clinical trials or regulatory approval.
Consumers in Virginia and other states should confirm that products comply with the rules where they live and where the products are sold. This is especially important when ordering hemp-derived cannabinoid products from online retailers based elsewhere.
CBG is used as an ingredient in cannabinoid products marketed for general wellness. Researchers are investigating its potential effects on stress, anxiety, mood, inflammation, and other biological processes. However, most proposed benefits have not been established through sufficiently large and rigorous clinical trials.
CBG is generally considered non-intoxicating and is not expected to produce the typical THC-related high. However, products containing CBG may also contain THC or other ingredients that affect the mind or body. Check the product's laboratory results and label.
No. CBG stands for cannabigerol, while CBD stands for cannabidiol. Both are cannabinoids found in cannabis plants, but they are chemically distinct and have different research profiles.
Not necessarily. The legality of a particular CBG product depends on federal requirements, state laws, the source of the cannabinoid, THC content, product formulation, and how the product is marketed. Always check the rules applicable to your location.
Some hemp-derived CBG products may be lawful in Virginia if they meet applicable federal and state requirements. Virginia's regulated hemp-product rules include a maximum of 2 milligrams of total THC per package for products produced or sold in the state under requirements effective August 15, 2026. Other product and retailer requirements may also apply.
A small 2024 human study reported short-term reductions in self-reported anxiety and stress following a 20 mg dose of CBG compared with placebo. More research is needed to establish its effectiveness, appropriate use, and long-term safety. CBG should not replace evidence-based treatment for an anxiety disorder.
There is not enough long-term clinical evidence to establish that daily CBG use is safe for everyone. Consult a healthcare professional before regular use, especially if you take medication or have an ongoing health condition.
CBG itself is not an established FDA-approved treatment for a medical condition. The FDA's regulatory framework for cannabis-derived products also means that hemp-derived ingredients are not automatically approved for use in dietary supplements, foods, or medicines.
Look for a clear ingredient list, an accurate amount of CBG per serving, independent laboratory testing, transparent THC content, and compliance with applicable local regulations. Avoid products that promise guaranteed results or claim to cure diseases.
Cannabigerol is an increasingly researched cannabinoid with potential applications in wellness, stress research, and other areas of human health. Early findings have generated interest, but the current scientific evidence is not strong enough to establish most advertised CBG benefits as proven medical outcomes.
For consumers in Virginia and across the United States, understanding the difference between hemp-derived CBG and other cannabis products is essential. Legal compliance depends on the product itself, applicable federal requirements, and state-specific rules.
If you are considering a CBG product, prioritize independent laboratory testing, transparent ingredient information, realistic expectations, and professional medical advice when appropriate.
The bottom line: CBG is a promising area of cannabinoid research, but more evidence is needed to determine its benefits, long-term safety, and best uses. Check the latest federal and state regulations before purchasing or selling hemp-derived CBG products.
Comments will be approved before showing up.
